


I hereby certify that this correspondence is being deposited as first-class mail with sufficient postage and is addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 21th day of October 2004 at Facsimile No.



(Signature of person transmitting)

A. David Joran (Reg. No. 37,858)

(Typed or printed name of person)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Sean Ekins

Examiner: Brusca, John S.

APPLICATION NO.: 09/804,176

Group Art Unit: 1631

FILING DATE: March 12, 2001

TITLE: PHARMACOPHORE MODELS FOR THE  
IDENTIFICATION OF THE CYP2D6 INHIBITORY  
POTENCY OF SELECTIVE SEROTONIN REUPTAKE  
INHIBITORS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE TO JULY 21, 2004 COMMUNICATION**

This response is submitted in response to the Office Action mailed July 21, 2004, and in further response to the Office Action mailed May 26, 2004, in connection with the above-identified application. A response is due October 21, 2004, with a two-month extension of time, petition for which is submitted herewith. Accordingly, this response is being timely filed.

Please make the following amendment in the subject application:

**In the Drawing:**

Please replace Figure 1 with substitute Figure 1, submitted herewith.


In response to the Examiner's requirement to elect a single disclosed species, applicant elected the species of Example 2 in the prior Communication. In further response, applicant hereby elects (d,l)-2-methoxy-4,5-methylenedioxyamphetamine as the one species of training compound for examination purposes, and applicant also elects "a partial least squares technique" as the one species of the optimum fit algorithm for examination purposes.

In response to the Drawing Requirement, applicant submits corrected Figure 1, to replace the Figure 1 originally submitted.

If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicants' undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: October 21, 2004



A. David Joran  
Attorney for Applicant(s)  
Reg. No. 37,858

Pfizer Inc  
Patent Department  
150 East 42nd Street – 5<sup>th</sup> Floor  
New York, NY 10017-5755  
(212) 733-3381